• Amy Turnquist, Partner, Life Sciences, BIP
• Barbara Salami, former VP/US Head, Commercial Excellence and Innovation, Novo Nordisk

We’re living through a domino effect of unprecedented events that have fundamentally altered the pharmaceutical landscape. From COVID’s acceleration of telehealth adoption to the semaglutide revolution reshaping patient expectations, a chain reaction of disruptions is pushing the industry toward true patient centricity—whether we’re ready or not. But success in this new environment requires more than adapting to change; it demands creating systems that serve both human and AI customers while maintaining definitional clarity around what patient experience actually means. Join industry leaders for an opening dialogue that examines how recent seismic shifts have created both opportunities and imperatives that no pharmaceutical marketer can afford to ignore.

• Rodrigo Cunha, Head of Performance Marketing, Google

This session led by the Head of Performance for the Healthcare Industry at Google will provide context on how Search behavior is changing, how Google Search is evolving with AI and what pharma needs to know to stay ahead of this AI evolution in Marketing.

• Dr. Osama Hashmi, MD, MPH, Dermatologist and Co-founder of Impiricus
• Dr. Muddasir Ayaz MD, Gastroenterologist
• Brooke Fleming, Commercial Omnichannel Marketing Leader, BeOne Marketing
• Randy Keim, Sr. Director, HCP Marketing, Sanofi

Healthcare professionals are overwhelmed by pharma noise and underwhelmed by meaningful, actionable support from the pharmaceutical industry. This session introduces a next-generation AI-powered engagement model that delivers unbiased, evidence-based resources—on demand, in context, and aligned with clinical decision-making for each HCP. We’ll share preference data and survey findings that reveal what physicians actually want from pharma and where current approaches fall short. Attendees will gain a roadmap that will help them shift from traditional pharmaceutical promotional tactics to a model that builds trust, provides real-time value, and partners in care delivery.

• Adam Daley, VP, Social Media, CG Life
• Kristine Saffrin, Associate Director, US Patient Marketing, Neurology, gMG, Alexion Pharmaceuticals, Inc.
• Lauren Lawhon, President and COO, HealthUnion

Rare disease marketers are pioneering ultra-precision strategies that go far beyond traditional targeting, building direct partnerships with patient advocacy groups to co-create content and programs rather than simply sponsoring them. This panel will explore how digital-first approaches—including sophisticated patient journey mapping and social listening—are helping marketers identify and support patients along the complex path to diagnosis. Learn how leading rare disease teams are innovating through value-based storytelling that combines patient-generated content with clinical messaging, all while navigating the unique regulatory landscape that defines this specialized space.

• Teresa Bruce, Global Medical Director, GSK
• Katherine Glavin, VP, Client Success and Delivery, Sermo

GSK and Sermo will share a Do THIS, not THAT playbook for marketers looking to maximize their HCP social strategy. Learn more about how marketers can apply a proven framework focused on engaging with confidence and adapting with agility, all while staying fully compliant.

• Lisa Bookwalter, CRO, Throtle
• Keith Matt, Group Vice President, PulsePoint

• Pete Dannenfelser, Director, Omnichannel Orchestration and Launch, Sanofi

In today’s fragmented media landscape, brands struggle with two critical challenges: reaching audiences when they’re most receptive and connecting disparate touchpoints to create meaningful engagement. This dynamic panel brings together industry experts to explore how forward-thinking organizations are solving both problems through intelligent timing strategies and unified data approaches.

• Berkeley Bethune, VP, Relationship Marketing, Healthline Media
• Erica Gusler, VP, Media Strategy & Planning, Klick Health
• Ashley Pippin, Product Director, Digital Health Solutions, Johnson and Johnson

New consumer research will be shared on exposure to broader content ranges and innovative experiences impacts audience confidence in their own health actions. This session explores how pharmaceutical brands can leverage these insights to meet consumers at different journey points, earning trust and shaping decisions while maintaining privacy standards. Panelists will discuss balancing personalization with privacy, creating experiences that impact health outcomes, and engaging audiences ready for action—from accessing savings programs to exploring treatment options.

• Matt Walsh, GM, Pharma, ixlayer
• Nandini Nayar, Global Digital Health and Innovation Lead, Sanofi

Direct-to-patient (DTP) programs are opening new possibilities for pharma to address barriers that patients have faced for decades. But what does it take to design solutions that are scalable, sustainable, and truly patient-centered? In this session, Nandini Nayar, Global Digital Health and Innovation Lead at Sanofi, will share her perspective in conversation with Matthew Walsh, General Manager of Biopharma at ixlayer, on the future of DTP. This discussion will highlight how the right partnerships, platforms, and guardrails can turn DTP from an experiment into a sustainable model for delivering education, access, and outcomes.

• Ericka Higgins-Tothe, Vice President, Omnichannel Marketing and Commercial Operations, Novo Nordisk
• Eric McCulley, Head of Portfolio Innovation, US Immunology, UCB Pharma
• Faruk Capan, CEO, EVERSANA INTOUCH & Chief Innovation Officer, EVERSANA
• Mark Bard, Co-Founder, The DHC Group

This fireside chat will address the critical question facing every pharmaceutical marketer: given everything we’ve learned today about disruption cascades, compound advantages, and patient empowerment—what should you prioritize when you return to the office tomorrow? Join us for a candid discussion about turning today’s insights into strategic action, identifying which innovations warrant immediate investment, and preparing your teams for a landscape where doing the marketing job exceptionally well means simultaneously exceeding business objectives while delivering measurable improvements in patient health outcomes.